Literature DB >> 31332503

Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4.

Hyo-Jin Kang1,2, Jung Hoon Kim3,4,5, Ijin Joo1,2, Joon Koo Han1,2,6.   

Abstract

PURPOSE: To determine the added value of CEUS on arterial phase non-hyperenhancement (APNHE) observations (LR-3 and LR-4) of CT/MRI in high-risk patients.
METHODS: Forty-three patients with APNHE observations (≥ 2 cm) from CT/MRI were prospectively enrolled in this IRB-approved study and underwent CEUS. All observations were assessed by LI-RADS for CT/MRI and CEUS. The hemodynamic findings were compared. The mean follow-up period was 11.8 ± 2.1 months. Reference standard was made on 34-APNHE observations based on biopsy (n = 2), surgery (n = 2), and follow-up image (n = 30).
RESULTS: The median of observation size was 2.3 cm (IQR 2.0-2.5 cm). Among the 43-APNHE observations, 12-observations (27.9%) were further presented as arterial phase hyperenhancement (APHE) in CEUS with early (n = 1, CEUS LR-M), late (n = 10, CEUS LR-5), or no (n = 1, CEUS LR-4) washout. Compared to CT, CEUS presented concordant enhancement patterns in 16 (44.4%) in AP and 20 (55.6%) in PVP, respectively. Similarly, 13 (59.1%) and 14 (63.6%) observations showed concordant enhancement patterns between CEUS and MRI in AP and PVP, respectively. Of the 34-APNHE observations with final diagnosis (hepatocellular carcinoma [HCC] n = 12; intrahepatic cholangiocarcinoma [IHCC], n = 1; non-malignancy, n = 21), 4 HCCs (33.3%) and 1 IHCC (100%) were additionally diagnosed by CEUS, while 1 non-malignant lesion (4.5%) was misdiagnosed as HCC by CEUS.
CONCLUSION: Adding CEUS to APNHE observations from CT/MRI would be useful not only for definitely diagnosing HCC (CEUS LR-5) but also for other malignancies (CEUS LR-M). The discordance of dynamic features between the LI-RADS for CEUS and CT/MRI may reflect the different properties of contrast media, although the systems are not interchangeable.

Entities:  

Keywords:  Contrast media; Diagnosis; Hepatocellular carcinoma; Liver; Ultrasonography

Mesh:

Substances:

Year:  2020        PMID: 31332503     DOI: 10.1007/s00261-019-02132-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  5 in total

1.  Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined?

Authors:  Hyo-Jin Kang; Jung Hoon Kim; Jeongin Yoo; Joon Koo Han
Journal:  Ultrasonography       Date:  2021-12-17

2.  Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.

Authors:  Hyo Jin Kang; Jeong Min Lee; Jeong Hee Yoon; Joon Koo Han
Journal:  Korean J Radiol       Date:  2020-11-03       Impact factor: 3.500

3.  Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging.

Authors:  Yeun-Yoon Kim; Ji Hye Min; Jeong Ah Hwang; Woo Kyoung Jeong; Dong Hyun Sinn; Hyo Keun Lim
Journal:  Ultrasonography       Date:  2022-01-28

Review 4.  CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together?

Authors:  Cosmin Caraiani; Bianca Boca; Vlad Bura; Zeno Sparchez; Yi Dong; Christoph Dietrich
Journal:  Biology (Basel)       Date:  2021-05-06

Review 5.  Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.

Authors:  Junghoan Park; Jeong Min Lee; Tae-Hyung Kim; Jeong Hee Yoon
Journal:  Clin Mol Hepatol       Date:  2021-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.